Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 815-819

  Lae M ^a   Couturier, J ^a   Oudard, S ^b   Radvanyi, F ^a   Beuzeboc, P ^a   Vieillefond, A ^c  

^a INSTITUT CURIE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

FISH; HER2; Immunohis to chemistry; Targeted therapy; Urothelial bladder carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CONTROLLED STUDY; CYSTECTOMY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STANDARD;

ANTINEOPLASTIC AGENTS; CARCINOMA; COHORT STUDIES; DRUG DELIVERY SYSTEMS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; UP-REGULATION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77951471947     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp488     Document Type: Article

References (30)

1. von der Maase H, Sengelov L, Roberts J et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
2. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
4. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
5. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
7. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-1977.
8. Underwood M, Bartlett J, Reeves J et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-2430.
9. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle- invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-2447.
10. Latif Z, Watters AD, Dunn I et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003; 89: 1305-1309.
11. Latif Z, Watters AD, Dunn I et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.
12. Coogan CL, Estrada CR, Kapur S, Bloom KJ. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004; 63: 786-790.
13. Caner V, Turk NS, Duzcan F et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14: 261-266.
14. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008; 130: 274-281.
15. Matsubara H, Yamada Y, Naruse K et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep 2008; 19: 57-63.
16. Miyamoto H, Kubota Y, Noguchi S et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000; 55: 679-683.
17. Krüger S, Weitsch G, Büttner H et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 2002; 21: 981-987.
18. de Pinieux G, Colin D, Vincent-Salomon A et al. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch 2004; 444: 415-419.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
20. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552-5564.
21. Vincent-Salomon A, MacGrogan G, Couturier J et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003; 42: 337-347.
22. Couturier J, Vincent-Salomon A, Nicolas A et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-1243.
23. Chivukula M, Bhargava R, Brufsky A et al. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 2008; 21: 363-368.
24. Cottu PH, Asselah J, Lae M et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008; 19: 595-597.
25. Simon R, Nocito A, Hübscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 1141-1146.
26. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94: 2169-2173.
27. Tuefferd M, Couturier J, Penault-Llorca F et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2007; 2: e1138.
28. Peyromaure M, Scotte F, Amsellem-Ouazana D et al. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol 2005; 48: 771-775.
29. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-2224.
30. Wülfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-2890.